

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

November 28, 2001

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced
that Bradford T. Smith, executive vice president of public
affairs, is scheduled to speak at the SG Cowen Global Health
Care Conference in Paris, France on Thursday, November 29 at
10:20 a.m. (4:20 a.m. EST). The presentation will be
webcast live, with a rebroadcast available for a period of
90 days, and may be heard online at www.labcorp.com.

At the conference, Mr. Smith will reiterate Company guidance
for 2001 and 2002, as filed in an 8K on October 22. Mr.
Smith will state, "For 2001, we expect revenue growth of
13.5 percent, EBITDA margins of approximately 21 percent of
sales and EPS growth of approximately 55 percent compared to
2000. For 2002, we expect to increase overall revenues by
approximately 12 percent compared to 2001 and we expect EPS
growth, as calculated under existing accounting rules, of
approximately 33 percent compared to 2001. In calculating
earnings and EPS under the new accounting rules regarding
goodwill, we expect the non-amortization of goodwill to have
an impact of approximately \$26 million in 2002, resulting in
an increase to EPS of approximately \$0.36."

Each of the above forward-looking statements is subject to
change based on various important factors, including without
limitation, competitive actions in the marketplace and
adverse actions of governmental and other third-party
payers. Further information on potential factors that could
affect LabCorp's financial results is included in the
Company's Form 10-K for the year ended December 31, 2000 and
subsequent SEC filings.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to

be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By: /s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President
and Secretary

Date: November 28, 2001